115 related articles for article (PubMed ID: 6495240)
1. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance.
Kirk JM; Bateman ED; Haslam PL; Laurent GJ; Turner-Warwick M
Thorax; 1984 Oct; 39(10):726-32. PubMed ID: 6495240
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis.
Behr J; Adelmann-Grill BC; Krombach F; Beinert T; Schwaiblmair M; Fruhmann G
Thorax; 1993 Jul; 48(7):736-42. PubMed ID: 8153923
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis.
Kirk JM; Heard BE; Kerr I; Turner-Warwick M; Laurent GJ
Coll Relat Res; 1984 May; 4(3):169-82. PubMed ID: 6205817
[TBL] [Abstract][Full Text] [Related]
4. Serum procollagen III peptide levels in subjects with sarcoidosis. A 5-year follow-up study.
Pohl WR; Thompson AB; Köhn H; Losch S; Umek H; Legenstein E; Kummer F; Rennard SI; Klech H
Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):412-7. PubMed ID: 1310576
[TBL] [Abstract][Full Text] [Related]
5. Type III and type I procollagen markers in fibrosing alveolitis.
Lammi L; Ryhänen L; Lakari E; Risteli J; Pääkkö P; Kahlos K; Lähde S; Kinnula V
Am J Respir Crit Care Med; 1999 Mar; 159(3):818-23. PubMed ID: 10051256
[TBL] [Abstract][Full Text] [Related]
6. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study.
Hubbard R; Johnston I; Britton J
Chest; 1998 Feb; 113(2):396-400. PubMed ID: 9498958
[TBL] [Abstract][Full Text] [Related]
7. [Serum type III procollagen peptide in patients with pneumoconiosis].
Okazaki I; Maruyama K; Okuno F; Suzuki H; Aoyagi K; Sera Y
J UOEH; 1983 Dec; 5(4):461-7. PubMed ID: 6679653
[TBL] [Abstract][Full Text] [Related]
8. Cryptogenic fibrosing alveolitis: prediction of fibrogenic activity from immunohistochemical studies of collagen types in lung biopsy specimens.
Bateman ED; Turner-Warwick M; Haslam PL; Adelmann-Grill BC
Thorax; 1983 Feb; 38(2):93-101. PubMed ID: 6344313
[TBL] [Abstract][Full Text] [Related]
9. Two serum markers of collagen biosynthesis as possible indicators of irreversible pulmonary impairment in farmer's lung.
Anttinen H; Terho EO; Myllylä R; Savolainen ER
Am Rev Respir Dis; 1986 Jan; 133(1):88-93. PubMed ID: 2935059
[TBL] [Abstract][Full Text] [Related]
10. Serum type III procollagen peptide in asbestos workers: an early indicator of pulmonary fibrosis.
Cavalleri A; Gobba F; Bacchella L; Luberto F; Ziccardi A
Br J Ind Med; 1988 Dec; 45(12):818-23. PubMed ID: 3219307
[TBL] [Abstract][Full Text] [Related]
11. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis.
Clark M; Cooper B; Singh S; Cooper M; Carr A; Hubbard R
Thorax; 2001 Jun; 56(6):482-6. PubMed ID: 11359966
[TBL] [Abstract][Full Text] [Related]
12. [Serum type III procollagen peptide in diagnosis of lung fibrosis due to silicosis and bleomycin toxicity].
Okuno F; Maruyama K; Okazaki I; Arai M; Suzuki H
J UOEH; 1985 Sep; 7(3):291-7. PubMed ID: 2416026
[TBL] [Abstract][Full Text] [Related]
13. [Serum type III procollagen peptide in tissue fibrosis].
Maruyama K
Rinsho Byori; 1985 Jan; 33(1):27-32. PubMed ID: 3990010
[No Abstract] [Full Text] [Related]
14. Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients. Pronounced augmented concentrations in the adult respiratory distress syndrome.
Entzian P; Hückstädt A; Kreipe H; Barth J
Am Rev Respir Dis; 1990 Nov; 142(5):1079-82. PubMed ID: 2240830
[TBL] [Abstract][Full Text] [Related]
15. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance.
Chesnutt AN; Matthay MA; Tibayan FA; Clark JG
Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):840-5. PubMed ID: 9310002
[TBL] [Abstract][Full Text] [Related]
16. [Significance of serum type III procollagen N-terminal peptide in patients with fibrotic lung disease].
Tanigawa S; Kinoshita Y; Kurosu H; Mogi M; Masutani M; Hayashi H; Okayasu M
Nihon Kyobu Shikkan Gakkai Zasshi; 1987 Nov; 25(11):1194-201. PubMed ID: 3449674
[No Abstract] [Full Text] [Related]
17. [Type III procollagen N-terminal peptide and type IV collagen-7S level in the serum and BALF of patients with non-Hodgkin's lymphoma before and after chemotherapy].
Niitsu N; Umeda M
Rinsho Ketsueki; 1994 Nov; 35(11):1267-75. PubMed ID: 7529840
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.
Johnson MA; Kwan S; Snell NJ; Nunn AJ; Darbyshire JH; Turner-Warwick M
Thorax; 1989 Apr; 44(4):280-8. PubMed ID: 2669218
[TBL] [Abstract][Full Text] [Related]
19. British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival.
Rudd RM; Prescott RJ; Chalmers JC; Johnston ID;
Thorax; 2007 Jan; 62(1):62-6. PubMed ID: 16769717
[TBL] [Abstract][Full Text] [Related]
20. Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans.
Chan TY; Hansell DM; Rubens MB; du Bois RM; Wells AU
Thorax; 1997 Mar; 52(3):265-70. PubMed ID: 9093344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
